INCB-123667 is under clinical development by Incyte and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase I drugs for Fallopian Tube Cancer have an 84% phase transition ...

CBX-12 is under clinical development by Cybrexa and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Cytoreductive surgery, whether performed as the initial treatment or following neoadjuvant chemotherapy (NACT) for advanced ...

How should we interpret recent findings about the possible role of the fallopian tubes in ovarian cancer? Robert DeBernardo, MD, gynecologic oncologist at Cleveland Clinic, gives us his take Share ...